JP2013508452A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508452A5 JP2013508452A5 JP2012536664A JP2012536664A JP2013508452A5 JP 2013508452 A5 JP2013508452 A5 JP 2013508452A5 JP 2012536664 A JP2012536664 A JP 2012536664A JP 2012536664 A JP2012536664 A JP 2012536664A JP 2013508452 A5 JP2013508452 A5 JP 2013508452A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- hydroxy
- heterocyclic ring
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- 150000002825 nitriles Chemical class 0.000 claims description 4
- -1 nitro, hydroxy Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims 1
- 208000035177 MELAS Diseases 0.000 claims 1
- 208000009564 MELAS Syndrome Diseases 0.000 claims 1
- 201000009035 MERRF syndrome Diseases 0.000 claims 1
- 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007625 mitochondrial abnormality Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000004043 oxo group Chemical group O=* 0.000 description 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000004181 carboxyalkyl group Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090101978 | 2009-10-26 | ||
| KR10-2009-0101978 | 2009-10-26 | ||
| KR20100098511 | 2010-10-08 | ||
| KR10-2010-0098511 | 2010-10-08 | ||
| PCT/KR2010/007344 WO2011052950A2 (en) | 2009-10-26 | 2010-10-25 | Pharmaceutical composition comprising indole compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508452A JP2013508452A (ja) | 2013-03-07 |
| JP2013508452A5 true JP2013508452A5 (enExample) | 2015-04-30 |
| JP5820813B2 JP5820813B2 (ja) | 2015-11-24 |
Family
ID=43922791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012536664A Active JP5820813B2 (ja) | 2009-10-26 | 2010-10-25 | インドール化合物を含む医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20120214804A1 (enExample) |
| EP (1) | EP2493469A4 (enExample) |
| JP (1) | JP5820813B2 (enExample) |
| KR (1) | KR101325272B1 (enExample) |
| CN (1) | CN102596198B (enExample) |
| AR (1) | AR078775A1 (enExample) |
| BR (1) | BR112012009894A2 (enExample) |
| MX (1) | MX338807B (enExample) |
| RU (1) | RU2557243C2 (enExample) |
| TR (1) | TR201204895T1 (enExample) |
| TW (2) | TW201119651A (enExample) |
| WO (1) | WO2011052950A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101304772B1 (ko) * | 2011-04-11 | 2013-09-05 | 인제대학교 산학협력단 | ＮｅｃｒｏＸ―５를 유효성분으로 포함하는 미토콘드리아 기능 조절용 조성물 |
| WO2013115457A1 (ko) * | 2012-01-31 | 2013-08-08 | 인제대학교 산학협력단 | ＮｅｃｒｏＸ를 함유하는 암 전이 억제용 조성물 |
| KR101400346B1 (ko) * | 2012-01-31 | 2014-05-30 | 인제대학교 산학협력단 | ＮｅｃｒｏＸ를 함유하는 암 전이 억제용 조성물 |
| CN113967215A (zh) * | 2014-04-18 | 2022-01-25 | Lg 化学株式会社 | 用于预防或治疗脂肪肝疾病的组合物 |
| CA2953387C (en) * | 2014-06-30 | 2023-11-28 | The Regents Of The University Of California | Ketobutyrate compounds and compositions for treating age-related symptoms and diseases |
| KR101633703B1 (ko) * | 2014-12-30 | 2016-06-27 | 한국원자력의학원 | necro X-5를 유효성분으로 포함하는 방사선 조사에 의한 세포손상 예방 또는 치료용 조성물 |
| CN107434819B (zh) * | 2017-02-15 | 2020-03-17 | 河北医科大学第二医院 | 吲哚-tempo缀合物及其在保护远隔器官对抗缺血再灌注损伤中的用途 |
| CN111278807B (zh) | 2017-08-17 | 2022-07-22 | 凯瑞康宁生物工程（武汉）有限公司 | 活性氧清除剂衍生物的制备及用途 |
| CN111356699B (zh) | 2017-09-04 | 2022-08-23 | 凯瑞康宁生物工程（武汉）有限公司 | 活性氧清除剂的制备及用途 |
| KR20200069259A (ko) | 2018-12-06 | 2020-06-16 | 국립암센터 | nc886을 포함하는 암살상 바이러스 활성 증진 또는 생산 증진용 조성물 |
| US11795147B2 (en) | 2019-08-26 | 2023-10-24 | Boehringer Ingelheim International Gmbh | Modulators of complex I |
| US20240009202A1 (en) | 2020-08-19 | 2024-01-11 | Mitoimmune Therapeutics Inc. | Mitochondria-targeted antioxidant as agent for treating pathologic inflammation caused by mabc-r infection |
| US20240043409A1 (en) | 2021-04-12 | 2024-02-08 | Mitoimmune Therapeutics Inc. | Crystalline forms of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indol-7-amine |
| EP4324829A4 (en) | 2021-04-12 | 2025-04-23 | MitoImmune Therapeutics Inc. | 5-[(1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL]-2-PHENYL-N-(TETRAHYDRO-2H-PYRAN-4-YL)-1H-INDOL-7-AMINE SULFATE AND A NEW CRYSTALLINE FORM THEREOF |
| WO2023182840A1 (ko) * | 2022-03-25 | 2023-09-28 | 주식회사 미토이뮨테라퓨틱스 | 항바이러스용 약학적 조성물 및 이의 용도 |
| DE102023204801A1 (de) * | 2023-05-23 | 2024-11-28 | Continental Reifen Deutschland Gmbh | Verbindung als Alterungsschutzmittel in Kautschukmischungen und Fahrzeugreifen |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6420429B1 (en) * | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| RU2182908C2 (ru) * | 1997-09-05 | 2002-05-27 | Лид Кемикал Ко., Лтд. | Стереоизомерные индольные соединения, способ их получения и их использование |
| EP1133487B1 (en) * | 1998-11-25 | 2004-09-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antioxidants |
| IL130169A (en) * | 1999-05-27 | 2006-08-20 | Neurim Pharma 1991 | Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them |
| AR039209A1 (es) * | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| WO2006112549A1 (ja) * | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物 |
| JP2008538586A (ja) * | 2005-04-21 | 2008-10-30 | グレン エー． ゴールドスタイン， | 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） |
| US20070161609A1 (en) * | 2006-01-10 | 2007-07-12 | Charles Buck | Use of mitochondrially targeted antioxidant in treatment and prevention of drug-induced liver disease |
| KR20090018593A (ko) * | 2007-08-17 | 2009-02-20 | 주식회사 엘지생명과학 | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 |
| RU2450001C2 (ru) * | 2007-12-20 | 2012-05-10 | Эл Джи Лайф Сайенсиз Лтд. | Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента |
| WO2009088192A2 (ko) * | 2008-01-04 | 2009-07-16 | Lg Life Sciences Ltd. | 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체 |
-
2010
- 2010-10-22 TW TW099136045A patent/TW201119651A/zh unknown
- 2010-10-22 TW TW102147720A patent/TWI535440B/zh active
- 2010-10-25 WO PCT/KR2010/007344 patent/WO2011052950A2/en not_active Ceased
- 2010-10-25 KR KR1020100104175A patent/KR101325272B1/ko active Active
- 2010-10-25 RU RU2012121815/04A patent/RU2557243C2/ru active
- 2010-10-25 JP JP2012536664A patent/JP5820813B2/ja active Active
- 2010-10-25 EP EP10827034.9A patent/EP2493469A4/en active Pending
- 2010-10-25 CN CN201080048324.2A patent/CN102596198B/zh active Active
- 2010-10-25 BR BR112012009894A patent/BR112012009894A2/pt not_active Application Discontinuation
- 2010-10-25 US US13/503,857 patent/US20120214804A1/en not_active Abandoned
- 2010-10-25 TR TR2012/04895T patent/TR201204895T1/xx unknown
- 2010-10-25 MX MX2012004504A patent/MX338807B/es active IP Right Grant
- 2010-10-26 AR ARP100103924A patent/AR078775A1/es not_active Application Discontinuation
-
2017
- 2017-02-24 US US15/441,998 patent/US10322135B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508452A5 (enExample) | ||
| JP2009538897A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| JP2012533546A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| RU2011149256A (ru) | Пестицидные композиции | |
| JP2015504067A5 (enExample) | ||
| RU2013119129A (ru) | Органические соединения | |
| JP2014525420A5 (enExample) | ||
| JP2011526917A5 (enExample) | ||
| JP2013531029A5 (enExample) | ||
| JP2014521701A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| RU2014146995A (ru) | Сульфонамидное производное и его медицинское применение | |
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| RU2017144495A (ru) | Противогельминтные депсипептидные соединения | |
| JP2010513322A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2014513727A5 (enExample) | ||
| RU2012121815A (ru) | Фармацевтическая композиция, содержащая индольное соединение |